Rheumatoid Arthritis – How Diet and Supplements Can Help

Care - The World | Dr. Galit Goldfarb


Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects the whole body and leads to cartilage, joint, and bone destruction.

RA is a very debilitating disease that may lead to difficulty doing daily activities. The pain and stiffness can be frustrating and challenging. 

Two percent of the global population suffers from this disease. RA is caused by genetic and environmental factors and takes many years before the onset of the disease is observed.

Diet and nutrient status have been found to have a central role in disease risk and progression.

In my recent video: “Rheumatoid Arthritis – How Diet and Supplements Can Help” I talk about what the research proves you should eat to reduce RA disease risk and development and I provide supplement recommendations.

Multiple Sclerosis Supplements, Herbs, Tinctures and Superfoods

Multiple Sclerosis Supplements, Herbs, Tinctures and Superfoods - YouTube


“Hello my loves, today I am sharing all the supplements, herbs, tinctures and superfoods I use to help me cope with Multiple Sclerosis. I am currently on Ocrevus which is my main source of treatment. Be sure to check in with your doctor or neurologist before taking anything new so as to be safe “

Fruit fly links sleep problems in autism to glial cells, blood-brain-barrier and serotonin

These Fighting Fruit Flies Are Superheroes of Brain Science | Deep Look -  YouTube

Bad sleep causes severe health issues and affects our ability to concentrate, memorize, and cope with challenging situations. Individuals with neurodevelopmental disorders such as autism and intellectual disability, frequently suffer from sleep problems. However, little is known about their underlying mechanisms. In Science Advances, a Dutch-American research team, coordinated by Radboudumc, now describes how these problems can arise. Mimicking two genetic causes of autism in fruit flies, they uncovered that flies show the same sleep problems as the patients, and that the disturbed sleep is caused by high levels of serotonin – also frequently observed in autism. Moreover, they found that the origin of high serotonin and sleep problems resides on the glial cells of the blood-brain barrier. This completely new information sheds light on sleep problems in humans and even suggests a possible treatment.

Poor sleep seriously affects cognitive abilities and quality of life. Already vulnerable individuals with autism and related neurodevelopmental disorders suffer particularly often from sleep disturbance, and with them their families as well. Yet, hardly any research has been conducted into the underlying mechanisms of these sleep problems. A Dutch-American team of researchers coordinated by professor Annette Schenck, in collaboration with professor Tjitske Kleefstra – both at Radboudumc – has investigated this problem in humans as well as in fruit flies. Schenck: “We first looked very closely at the sleep problems in two specific patient groups with neurodevelopmental disorders. They have mutations in the CHD8 gene, a leading genetic cause of autism, or in a closely related gene, CHD7, giving raise to CHARGE syndrome. We see that the bad sleep in these disorders particularly comes from problems falling and staying asleep, which causes night awakenings and low sleep quality. We call this problem sleep fragmentation. It is frequent in autism in general, but even more frequent in the individuals with mutations in CHD8 or CHD7. According to affected families, these sleep problems are one of their biggest problems in daily life management. This motivated us to study sleep disturbances, in context of these genes and disorders further”.

From humans to fruit flies

To be able to look into brains, investigate problems, and test interventions, researchers turn to animal models. In the fruit fly, an animal model that has led to multiple Nobel prizes, CHD8 and CHD7 are represented by a single gene termed kismet. Mutations in kismet in the fruit fly can therefore tell a lot about mutations in those two “orthologous” genes in humans. Mireia Coll-Tané, researcher in Schenck’s group and lead author of the study published in Science Advances: “We see that flies with mutations in kismet have problems staying asleep, waking up during night extremely frequently. They show the same characteristics that we see in people with mutations in CHD8 and CHD7.”

Not the neurons, but the glial cells

Schenck’s research group is specialized in fruit fly research on genes causing neurodevelopmental disorders. They routinely generate flies with mutations in genes that correspond to the disease genes, and look at changes in behaviors or other properties of the nervous system that are present in both humans and flies. Schenck: “when Mireia found the sleep fragmentation to be present also in flies, we knew that can use our model with all of its advantages to find out where this problem comes from”. They found that kismet is important for good sleep of adult flies but also already earlier during development, and that the adult sleep defects result from decreased kismet during the developmental period. Coll-Tané: “We also found that kismet was not important in the neurons, the cells that are classically seen to regulate behavior, but in the other main cell type present in the brain: the glial cells. Glia have many important functions, such as supporting neurons, cleaning up waste and contributing to the blood-brain barrier. We saw that kismet is important, already in early development, in a group of only 300 glial cells that form the blood-brain barrier in the fly. They are the origin of the sleep fragmentation.”

Surprising role for serotonin

Often the neurotransmitter dopamine plays a role in sleeping problems. This study also looked at this, but dopamine levels were normal. In contrast, the neurotransmitter serotonin appeared to be important. Coll-Tané: “When we reduce kismet specifically in glia, we found the concentration of serotonin in fruit fly heads to be doubled. This is a very interesting finding because increased serotonin, also referred to as hyperserotonemia, is one of the most commonly found biomarkers in autism.” In a series of further genetic and drug experiments, the researchers provided evidence that the increased serotonin levels during development are responsible for kismet’s sleep fragmentation. Coll-Tané: “Our work has linked a leading genetic cause of autism to a frequent biomarker and an important clinical complaint in autism. We propose that our identified mechanism is relevant to autism more widely”.

Future therapy?

An important question is whether the sleep problems associated with the developmental disorders can be tackled after all. It must be a treatment that works in adults (ie after development), and that is non-invasive and safe. Schenck: “Our co-authors in Philadelphia recently developed sleep-restriction therapy for fruit flies – SRT for short. An equivalent intervention is widely used in humans, in otherwise healthy individuals with insomnia. But it is rarely applied to autism and neurodevelopmental disorders, perhaps because sleep defects are considered an inevitable consequence of the genetic mutations. But the behavioral therapy succeeded! A simple light regime mimicking shorter nights made the flies sleeping better, effectively reversing the sleep fragmentation. And this despite that the origin of the problems lies earlier in development.”

Further research in humans

With the article in Science Advances, further research in humans is obvious. Clinical geneticist Kleefstra: “We have already shown in our article that CHD7 and CHD8 are expressed in the human blood-brain barrier, both during development and adulthood. Now we aim to collect further clinical data and apply SRT to these patients, in close collaboration with the expert sleep clinic Kempenhaeghe in Heeze. Together, we are expanding our ‘human-to-fruit-fly-and-back’ strategy to a number of other disorders.” Clearly, the path to more fascinating sleep research in flies and humans is up for grabs with this publication.

Research advances one step closer to stem cell therapy for type 1 diabetes

This image shows functional beta cells made from human pluripotent stem cells. Insulin (red) and NKX6.1 (green) indicate two proteins produced by beta cells. CREDIT Salk Institute

 Type 1 diabetes, which arises when the pancreas doesn’t create enough insulin to control levels of glucose in the blood, is a disease that currently has no cure and is difficult for most patients to manage. Scientists at the Salk Institute are developing a promising approach for treating it: using stem cells to create insulin-producing cells (called beta cells) that could replace nonfunctional pancreatic cells.

In a study published on June 7, 2021, in the journal Nature Communications, the investigators reported that they have developed a new way to create beta cells that is much more efficient than previous methods. Additionally, when these beta cells were tested in a mouse model of type 1 diabetes, the animals’ blood sugar was brought under control within about two weeks.

“Stem cells are an extremely promising approach for developing many cell therapies, including better treatments for type 1 diabetes,” says Salk Professor Juan Carlos Izpisua Belmonte, the paper’s senior author. “This method for manufacturing large numbers of safe and functional beta cells is an important step forward.”

In the current work, the investigators started with human pluripotent stem cells (hPSCs). These cells, which can be derived from adult tissues (most often the skin), have the potential to become any kind of cell found in the adult body. Using various growth factors and chemicals, the investigators coaxed hPSCs into beta cells in a stepwise fashion that mimicked pancreatic development.

Producing beta cells from hPSCs in the lab is not new, but in the past the yields of these precious cells have been low. With existing methods, only about 10 to 40 percent of cells become beta cells. By comparison, techniques used to create nerve cells from hPSCs have yields of about 80 percent. Another issue is that if undifferentiated cells are left in the mix, they could eventually turn into another kind cell that would be unwanted.

“In order for beta cell-based treatments to eventually become a viable option for patients, it’s important to make these cells easier to manufacture,” says co-first author Haisong Liu, a former member of the Belmonte lab. “We need to find a way to optimize the process.”

To address the problem, the researchers took a stepwise approach to create beta cells. They identified several chemicals that are important for inducing hPSCs to become more specialized cells. They ultimately identified several cocktails of chemicals that resulted in beta cell yields of up to 80 percent.

They also looked at the ways in which these cells are grown in the lab. “Normally cells are grown on a flat plate, but we allowed them to grow in three dimensions,” says co-first author Ronghui Li, a postdoctoral fellow in the Belmonte lab. Growing the cells in this way creates more shared surface area between the cells and allows them to influence each other, just as they would during human development.

After the cells were created, they were transplanted into a mouse model of type 1 diabetes, The model mice had a modified immune system that would not reject transplanted human cells. “We found that within two weeks these mice had a reduction of their high blood sugar level into normal range,” says co-first author Hsin-Kai Liao, a staff researcher in the Belmonte lab. “The transplanted hPSC-derived beta cells were biologically functional.”

The researchers will continue to study this technique in the lab to further optimize the production of beta cells. More research is needed to assess safety issues before clinical trials can be initiated in humans. The investigators say the methods reported in this paper may also be useful for developing specialized cells to treat other diseases.